TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Abnormalities of laboratories
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: feasibility of treatment regimen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stereotypic Behaviors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Comparison of signals between groups
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean ventricular rate at rest and during exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: serum low-density lipoprotein (LDL) cholesterol concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Participants Retained to Topiramate Treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Supine pulse rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Sleep Paralysis Experiences
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Glasses purchase proportion
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Composite of death from cardiovascular cause, myocardial infarction, stroke and bleeding grade ≥ 2
Endpoint domain: Mortality/survival
Primary endpoint: Change in Diabetes Risk Awareness
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Symptoms of Post-Traumatic Stress Disorder (PTSD)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Histologic NAFLD activity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of GU and GI Acute Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of GU and GI Late Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Disease-free survival as measured by the Phoenix definition
Endpoint domain: Mortality/survival
Primary endpoint: Change in TMS Plasticity Measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive Performance (RBANS)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Cognitive Performance (DKEFS)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Cognitive Performance (Digital Span)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: AUC (0-last) of Narlaprevir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of Narlaprevir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tmax of Narlaprevir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Fugl-Meyer Assessment Upper Extremity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Barthel Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Box and Block Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Visual Analogue Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Electroencephalography power in alpha band
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Event free survival of the composite of Cardiovascular or unexplained death, Stroke, Systemic embolism, Bleeding
Endpoint domain: Mortality/survival
Primary endpoint: Change from baseline handgrip strength at 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline physical performance-gait speed- at 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline physical performance-SPPB- at 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Contra-Movement Jump
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Unified Spasmodic Dysphonia Rating Scale (USDRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of children started on asthma medication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Score for Overall Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Pruritus Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change from baseline in weekly mean of the pain intensity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acute anatomical changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Acute geometric changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of increased maximal diameter of enrolled paraclinoid aneurysms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of rupture of enrolled paraclinoid aneurysms
Endpoint domain: Mortality/survival
Primary endpoint: Atrial arrhythmic events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: change in endothelial dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: change in blood brain barrier disruption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: change in neuronal injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: New York Heart Association class categories
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Levels of suPAR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease progression in IPF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of pain
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Prevalence of GABHS in acute pharyngitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Lipoprotein cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Low-density lipoprotein particle size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: reduction in anxiety score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: In-hospital incidence of death
Endpoint domain: Mortality/survival
Primary endpoint: Duration of Sensory Blockade
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiovascular Reactivity (CVR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of individuals retained in treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percent of infants born with Neonatal Abstinence Syndrome (NAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants who Achieve Combined Remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fusion Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: questionnaire scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: logMAR Visual Acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immune cell population
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Duration of stay in intensive care unit
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Number of additional unplanned respiratory therapy treatment
Endpoint domain: Adverse events/effects
Primary endpoint: CD34+/ total MNC percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Colony Formation Capacity - Numbers of Colony formed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Migratory function in response to SDF1α
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Targeted gene expression of EPCs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline of PASP under hypoxic conditions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number and proportion of patients experiencing a respiratory adverse event
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of biopsy confirmed acute rejection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: LMA insertion success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Myocardial cell damage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Distant Brain Metastasis-free Survival (DBMFS)
Endpoint domain: Mortality/survival
Primary endpoint: Maximum tolerated dose of pemetrexed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Post Traumatic Stress Symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Recurrence of stroke or TIA
Endpoint domain: Mortality/survival
Primary endpoint: Change in Paffenbarger Exercise and Physical Activity Index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Recent Thymic Emigrant Cells in Peripheral Blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Density of Tumor-infiltrating Cluster of Differentiation (CD8+) Cells (TILs) in Tumor Tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mandibular movements (mobility index)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in LDL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence and severity of AEs/SAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Cognitive function (MMSE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Psychiatric symptoms (SCOPA-PC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Had AKI (Acute Kidney Injury)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of Participants With Naloxone Side Effects
Endpoint domain: Adverse events/effects
Primary endpoint: Safety of VBY-376
Endpoint domain: Adverse events/effects
Primary endpoint: Success Rate of Reactivation of Epidural Catheter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: p-NRS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LEFS score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Adult Myopathy Assessment Tool (AMAT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ERP response size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ERP response timing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Eye-tracking: target accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Eye-tracking: speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall incidence of adverse events and adverse drug reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Sustained virologic response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of ALT (alanine transaminase)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: development of significant pulmonary toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: complete responses (all cohorts)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Marijuana Craving Questionnaire - Short Form (MCQ-SF)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Clinical Global Impression (CGI)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Montgomery Åsberg Depression Rating Scale (MADRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Psychotic Depression Scale (PDS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Participants Achieving PASI 90 Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Reduction of cardiac ischemic events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Bacterial Bioburden
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Diabetes Treatment Satisfaction Questionnaire (DTSQc) Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Median Progression-free survival (PFS)
Endpoint domain: Mortality/survival
Primary endpoint: Recurrent Dislocation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in pure tone audiometry score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean percent change in Hemoglobin A1c (HbA1c)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma ACTH concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Changes in pain ratings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Contamination rate of parents' cellphones
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Types of bacteria on cell phones
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Effectiveness of antimicrobial gel in reducing transmission
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in the Nepean dyspepsia index-Korean version scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Time to perform fiberoptic intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percent time spent </= 3.9 mmol/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: TFPI level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change from Baseline: Aspartate aminotransferase (AST)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change from Baseline: Alanine aminotransferase (ALT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change from Baseline: gamma-Glutamyl transferase (GGT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change from Baseline: Estimated glomerular filtration rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change from Baseline: Blood urea nitrogen to creatinine ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Improvement on the Geriatric Depression Scale (GDS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Osteoprotegin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of Typing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Treatment Emergent Serious Adverse Event (TESAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Confirmed Inhibitor Development
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy of ozone treatment in diabetic foot
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of ozone treatment in diabetic foot
Endpoint domain: Adverse events/effects
Primary endpoint: Shoulder pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Early Recovery
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Intermediate recovery
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Proportion of patients meeting ABC pathway criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite of cardiovascular death, all stroke, worsening of heart failure, acute coronary syndrome, and emergency visits due to AF
Endpoint domain: Mortality/survival
Primary endpoint: Change in trough sitting diastolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change From Baseline in the 4-Step Ascend Velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency and Severity of Suicidal Ideation
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency and Severity of Suicidal Behavior
Endpoint domain: Adverse events/effects
Primary endpoint: immune cell phenotypes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: antigen-specific t-cell responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean Percentage Change in sPGA and BSA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in OSDI scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: changes in sexual well-being
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Liebowitz Social Anxiety Scale (LSAS) Total Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of Participants Experiencing Drug-Related Grade 3-4 Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Experiencing Drug-Related Grade 3-4 Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Experiencing Abnormal Hepatic Laboratory Test Results
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Experiencing Toxicity Grade 3-4 Laboratory Test Results
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of ruptured or eroded plaques at infarct related lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percent of covered stent struts by OCT in infarct-related lesion at 9 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in HIV-1 RNA viral load
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: % patients per GERD patient segment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain intensity (100 mm VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 6 minute walk test, 6MWT, distance (m)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disability rating index, DRI. Function past week %
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Barthel ADL Index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Eq-5d (Euroqol)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Improvement in Depressive Symptoms: Remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Active Patient Utilization
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Presence and number of germ cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Cumulative treatment failure rate (HbA1c≥7.0%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Severity of Lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Reduction of Temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects With Treatment-emergent Adverse Events (TEAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Subjects With Treatment-emergent Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects With Treatment-emergent Serious Adverse Events (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Functional Assessment Staging (FAST) score change
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: St. George's Respiratory Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Pharmacokinetic profile (AUC, tmax, Cmax, t1/2, Rac)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Equilibrium Score (ES)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensory Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Verbal Reaction Time (VRT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sun Protection Factor (SPF) efficacy before immersion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Sun Protection Factor (SPF) efficacy after immersion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes